Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CureVac N.V (CVAC) Accounts Payables: 2019-2025

Historic Accounts Payables for CureVac N.V (CVAC) over the last 4 years, with Jun 2025 value amounting to $8.6 million.

  • CureVac N.V's Accounts Payables rose 6.07% to $8.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $8.6 million, marking a year-over-year increase of 6.07%. This contributed to the annual value of $18.5 million for FY2024, which is 64.29% down from last year.
  • Per CureVac N.V's latest filing, its Accounts Payables stood at $8.6 million for Q2 2025, which was down 13.47% from $9.9 million recorded in Q1 2025.
  • CureVac N.V's 5-year Accounts Payables high stood at $146.1 million for Q4 2021, and its period low was $8.1 million during Q2 2024.
  • Moreover, its 3-year median value for Accounts Payables was $14.7 million (2023), whereas its average is $17.6 million.
  • Per our database at Business Quant, CureVac N.V's Accounts Payables spiked by 121,071.74% in 2021 and then tumbled by 77.42% in 2023.
  • Over the past 5 years, CureVac N.V's Accounts Payables (Quarterly) stood at $146.1 million in 2021, then slumped by 48.70% to $75.0 million in 2022, then tumbled by 31.05% to $51.7 million in 2023, then slumped by 64.29% to $18.5 million in 2024, then grew by 6.07% to $8.6 million in 2025.
  • Its Accounts Payables was $8.6 million in Q2 2025, compared to $9.9 million in Q1 2025 and $18.5 million in Q4 2024.